# A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.

> **NCT00145171** · PHASE3 · COMPLETED · sponsor: **Mylan Bertek Pharmaceuticals** · enrollment: 56 (—)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** apomorphine HCl injection

## Key facts

- **NCT ID:** NCT00145171
- **Lead sponsor:** Mylan Bertek Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** —
- **Final completion:** 2002-08
- **Target enrollment:** 56 (—)
- **Last updated:** 2005-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00145171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00145171, "A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00145171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*